Velocity Composites delivered a robust investor update, highlighting continued operational improvements and positive financial momentum. Revenue for the half year stood at £10.4 million, slightly down due to temporary programme rebalancing, but offset by strong gross margin recovery driven by operational efficiencies and successful inflation pass-throughs. The company achieved a second consecutive period of positive EBITDA, marking a post-pandemic milestone, with cash reserves of £1.2 million and access to a £3 million invoice discounting facility, ensuring ample liquidity for growth. Velocity remains strategically aligned with aerospace market recovery, particularly in the A350 and 737 platforms, and is poised to benefit from accelerating aircraft production rates and increased outsourcing from OEMs. The US facility is now fully operational, with enhanced capacity and supporting defence-related programmes, while European operations continue to improve gross margins through automation and cost control. The company reiterated its long-term targets of 25%+ gross margin and 10% operating profit, supported by a growing pipeline of civil and defence contracts. Velocity’s technology-driven, lean supply chain model and diversified programme base position it to scale sustainably amid industry tailwinds. Investors were also reassured by disciplined cost management, steady deleveraging of COVID-related loans, and increased director shareholding. The business remains focused on converting a strong bid pipeline into contracted revenue while building long-term customer relationships across global aerospace markets.

Afentra has provided a detailed investor update outlining its strategic entry into Angola’s onshore Kwanza Basin, highlighting its newly secured operatorship of Block CON4 and growing presence across Blocks CO15 and CO19. The company emphasized the basin’s proven petroleum system, with over 400 million barrels of oil in place and substantial redevelopment and exploration potential. The CON4 block alone hosts 200 million barrels of oil in place, with infrastructure in place to enable fast-track commercialization and early production. Aventra’s phased reactivation plan includes well re-entries, new drilling, and application of modern technology to unlock value from legacy assets. The company also noted the low-cost nature of onshore operations and robust logistics, including proximity to the Luanda refinery. Supported by gravity-based exploration technology and strong regulatory relationships, Aventra sees the Kwanza Basin as a high-impact, low-risk opportunity. With a clear growth strategy, continued hedging discipline, and plans for share buybacks, Aventra reaffirmed its commitment to generating shareholder value through both organic field development and inorganic acquisitions.

TPXimpact Holdings PLC (AIM:TPX) delivered its FY2025 investor update, highlighting strong operational resilience despite an 8% revenue decline to £77.3m. The company achieved a 21% increase in adjusted EBITDA to £5.6m, improving margins to 7.3%, supported by strategic restructuring, improved utilisation, and disciplined cost management. TPX maintained solid banking covenant compliance, with net debt at £8.5m and leverage stable at 1.5x. The company remains well-positioned for growth, underpinned by its simplified three-unit operating model, strong client retention, and a robust public sector pipeline following the UK government's comprehensive spending review. With consistent demand across key sectors - health, housing, planning, and infrastructure - TPX expects market confidence to build into H2. ESG credentials remain strong, with carbon emissions down 23%, 51% female workforce representation, and 86% employee retention. Recent digital transformation wins include NHS Sussex, Manchester City Council, and the Trussell Trust, demonstrating TPX’s purpose-led approach and delivery capability. The group reaffirms its guidance of £6-7m adjusted EBITDA for FY2026 and continues to reduce net debt while investing in AI-driven service innovation. As TPX enters year three of its transformation plan, it is focused on sustainable growth, operating efficiency, and margin enhancement. Investors can anticipate a refreshed three-year strategy in autumn 2025.

NewRiver REIT PLC (LSE:NRR) delivered a transformational FY25, underpinned by the strategic acquisition of Capital & Regional, which increased gross assets by 65% and drove a 25% rise in underlying funds from operations (UFFO). The £151m acquisition, completed at a 14% discount to net asset value, has proven highly earnings-accretive, with further EPS growth anticipated in FY26 and FY27. Operationally, the portfolio outperformed the UK retail market, achieving 4.9% consumer spend growth, 96.1% occupancy, and 90% tenant retention. Net rental income rose, leasing deals were 17.5% above previous rents, and cost synergies of £6.2m remain on track for FY26 delivery. The REIT's capital partnerships arm now manages £2.4bn in assets across 78 retail assets, contributing 10% of projected FY26 UFFO with strong growth potential. Post year-end, LTV was reduced to 38% following the £58.8m Abbey Centre disposal, reinforcing balance sheet strength. Dividends increased to 6.5p per share, yielding over 8%, and covered 125% by earnings. With robust debt metrics, low cost of capital (3.5%), growing capital-light income streams, and improving UK retail dynamics, NewRiver is well-positioned to deliver sector-leading shareholder returns through sustainable income growth, capital recycling, and valuation upside.

Mobius Investment Trust PLC (LSE:MMIT) delivered a detailed investor update outlining its differentiated approach to generating long-term capital growth across emerging markets. Despite a volatile macroeconomic environment, the Trust maintains high conviction in select small and mid-cap companies with strong margins, governance, and innovation-led business models - particularly in India, Taiwan, and Southeast Asia. The portfolio, concentrated in fewer than 30 holdings, has achieved a 44.4% return since inception and consistently outperformed both the MSCI Emerging Markets Index and its LSE-listed peers. With earnings growth in emerging markets forecast at 14-16% for 2025-2026, Mobius sees an inflection point driven by attractive valuations, resilient GDP growth, favourable demographics, and global decoupling from overvalued developed markets. Key holdings include leaders in wealth management, atomic force microscopy, electronic shelf labeling, and steel-based infrastructure. The Trust actively avoids overexposed sectors and geographies like China, maintains liquidity discipline, and integrates ESG factors into its investment process. Management is exploring portfolio gearing to enhance upside potential and continues to focus on delivering superior risk-adjusted returns. With a high active share and deep on-the-ground research, Mobius is well-positioned to benefit from innovation-led value creation across emerging markets. Investors are encouraged to view the current discount as a long-term opportunity.

Poolbeg Pharma PLC (AIM:POLB) delivered a compelling investor update highlighting major clinical milestones and strategic advancements. The company successfully completed an oversubscribed £4.865 million fundraise, providing a strong cash runway through 2027. Key developments include the launch of two high-potential clinical programmes: POLB 001 for the prevention of cytokine release syndrome (CRS) in cancer immunotherapy, and an oral GLP-1 obesity treatment targeting the growing demand for convenient, non-injectable weight-loss solutions. POLB 001, an orally available p38 MAP kinase inhibitor, has received FDA Orphan Drug Designation and is poised to enter a Phase 2 trial in multiple myeloma patients. The trial, supported by top-10 pharma companies providing drug supply, could unlock a $10bn market opportunity by addressing CRS-related bottlenecks in cancer treatment. Simultaneously, the GLP-1 programme, leveraging validated oral delivery technology, aims to capture market share in the expanding obesity drug sector, projected to reach $150bn by 2031. With rapid trial timelines, interim data from both studies are expected in H1 2026, offering near-term value inflection points. Backed by a seasoned leadership team, robust IP portfolio, and strategic pharma engagement, Poolbeg is positioned for transformative growth and partnership opportunities. This investor presentation underscores the company’s clear clinical execution strategy, pipeline strength, and potential to deliver shareholder value in the biotech sector.

Motorpoint Group PLC (LSE:MOTR) delivered a robust FY25 investor update, highlighting a return to profitable growth and renewed confidence in its strategic direction. Retail unit sales increased 14%, with total revenue up 8% year-on-year, driven by improved stock availability, dynamic pricing, and a strong omnichannel offering. Gross profit per unit rose nearly 10% to £1,300, and margins strengthened to 7.9%, reflecting disciplined inventory management and data-led decision-making. The company reported a significant turnaround in pre-tax profit and ended the year with £7 million net cash, maintaining a capital-light balance sheet. Strategic priorities include expanding store footprint (targeting 30 sites), enhancing digital capabilities, and growing high-margin services such as "Sell Your Car" and in-house aftersales. Customer satisfaction reached record levels with a Net Promoter Score of 84, underlining strong brand loyalty. With market share gains, progressive dividend reinstatement, a second share buyback underway, and rising website traffic and digital conversions, Motorpoint is well-positioned for sustained EBITDA growth and shareholder value creation. Management remains optimistic as macro headwinds ease and supply conditions normalize, reinforcing a clear growth strategy built on operational efficiency, digital transformation, and customer-centricity.

KEFI Gold and Copper Plc (AIM:KEFI) provided a comprehensive investor update detailing significant progress toward project execution at its flagship Tulu Kapi gold project in Ethiopia. The company confirmed that parliamentary ratification in May was a key milestone, unlocking final stages of project financing and enabling the sequencing of contractual closings. Management highlighted that over $320 million in financing is now entering the final stages, with independent certifications and definitive agreements targeted for completion by July, followed by drawdown and mobilisation shortly after. KEFI emphasized its robust stakeholder alignment across government, contractors, and institutional investors, with construction preparations already underway. CEO Harry Anagnostaras-Adams reaffirmed that field activities are ramping up and that all parties are focused on disciplined execution despite regional complexities. The company addressed shareholder concerns over dilution, remuneration, and listing strategy, reiterating its long-term value creation potential and commitment to transparency. The project is expected to scale to 160,000 ounces in year one, with potential to exceed 200,000 ounces annually. KEFI also noted emerging opportunities within its Saudi portfolio and ongoing development of local investment frameworks, including a prospective listing of its Ethiopian subsidiary. With contractual finalisation imminent, KEFI is positioned at a critical inflection point, targeting first production and long-term cash flow generation to support potential future dividends. Investors were encouraged by institutional support and the company’s resilience navigating complex frontier markets, underscoring KEFI’s unique role as a first mover in Ethiopia’s mining sector.